The unique biological features of the marine product Yondelis™ (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring

Oncology Research

Volumn 14, Issue 11-12, 2004, Pages 579-587

  Erba, E ^a   Cavallaro, E ^a   Damia, G ^a   Mantovani, R ^b   Di Silvio, A ^b   Di Francesco, A M ^c   Riccardi, R ^c   Cuevas, C ^d   Faircloth, G T ^e   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d PHARMAMAR S A   (Spain)

^e PharmaMar USA Inc   (United States)

Author keywords

Cell cycle; ET 743 analog; Nucleotide excision repair

Indexed keywords

DNA; DNA BINDING PROTEIN; ET 637; GUANINE; HEAT SHOCK PROTEIN 40; NATURAL PRODUCT; OLIGONUCLEOTIDE; TRABECTEDIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BIOLOGICAL ACTIVITY; CELL CYCLE; CELL CYCLE S PHASE; CELL LINE; CHEMICAL STRUCTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; EXCISION REPAIR; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; TEMPERATURE DEPENDENCE;

EID: 19944432133     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040042707925     Document Type: Article

References (21)

1. Rinehart, K. L.; Holt, T. G.; Fregeau, N. L.; Stroh, J. G.; Keifer, P. A.; Li, L. H.; Martin, D. G. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate. J. Org. Chem. 55:4512-4515; 1990.
2. Guan, Y.; Sakai, R.; Rinehart, K. L.; Wang, A. H. J. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinate. J. Biomol. Struct. Dyn. 10:793-818; 1993.
3. Jimeno, J. M.; Faircloth, G.; Cameron, L.; Meely, K.; Vega, E.; Gomez, A.; FernandezSousa-Faro, J. M.; Rinehart, K. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Future 21:1155-1165; 1996.
4. Valoti, G.; Nicoletti, M. I.; Pellegrino, A.; Jimeno, J.; Hendriks, H.; D'Incalci, M.; Faircloth, G.; Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4:1977-1983; 1998.
5. Hendriks, H. R.; Fiebig, H. H.; Giavazzi, R.; Langdon, S. P.; Jimeno, J. M.; Faircloth, G. T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 10:1233-1240; 1999.
6. D'Incalci, M.; Erba, E.; Damia, G.; Galliera, E.; Carrassa, L.; Marchini, S.; Mantovani, R.; Tognon, G.; Fruscio, R.; Jimeno, J.; Faircloth, G. T. Unique features of the mode of action of ET-743. Oncologist 7:210-216; 2002.
7. Pommier, Y.; Kohlhagen, G.; Bailly, C.; Waring, M.; Mazumder, A.; Kohn, K. W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinate. Biochemistry 35:13303-13309; 1996.
8. Moore, B. M., II; Seaman, F. C.; Hurley, L. H. NMR-based model of an ecteinascidin 743-DNA adduct. J. Am. Chem. Soc. 119:5475-5476; 1997.
9. Zewail-Foote, M.; Hurley, L. H. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42:2493-2497; 1999.
10. Bonfanti, M.; La Valle, E.; Fernandez Sousa Faro, J. M.; Faircloth, G.; Caretti, G.; D'Incalci, M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 14:179-186; 1999.
11. Minuzzo, M.; Marchini, S.; Broggini, M.; Faircloth, G. T.; D'Incalci, M.; Mantovani, R. Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc. Natl. Acad. Sci. USA 97:6780-6784; 2000.
12. Jin, S.; Gorfajn, B.; Faircloth, G.; Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA 97: 6775-6779; 2000.
13. Friedman, D.; Hu, Z.; Kolb, E. A.; Gorfajn, B.; Scotto, K. W. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 62:3377-3381; 2002.
14. Damia, G.; Silvestri, S.; Carrassa, L.; Filiberti, L.; Faircloth, G. T.; Liberi, G.; Foiani, M.; D'Incalci, M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer 92:583-588; 2001.
15. Erba, E.; Bergamaschi, D.; Bassano, L.; Damia, G.; Ronzoni, S.; Faircloth, G. T.; D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37:97-105; 2001.
16. Takebayashi, Y.; Pourquier, P.; Zimonjic, D. B.; Nakayama, K.; Emmert, S.; Ueda, T.; Urasaki, Y.; Kanzaki, A.; Akiyama, S. I.; Popescu, N.; Kraemer, K. H.; Pommier, Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7:961-966; 2001.
17. Zewail-Foote, M.; Li, V. S.; Kohn, H.; Bearss, D.; Guzman, M.; Hurley, L. H. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8:1033-1049; 2001.
18. Erba, E.; Bassano, L.; Di Liberti, G.; Muradore, I.; Chiorino, G.; Ubezio, P.; Vignati, S.; Codegoni, A.; Desiderio, M. A.; Faircloth, G.; Jimeno, J.; D'Incalci, M. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br. J. Cancer 86:1510-1517; 2002.
19. Faretta, M.; Bergamaschi, D.; Taverna, S.; Ronzoni, S.; Pantarotto, M.; Mascellani, E.; Cappella, P.; Ubezio, P.; Erba, E. Characterization of cyclin B1 expression in human cancer cell lines by a new three-parameter BrdUrd/cyclin B1/DNA analysis. Cytometry 31:53-59; 1998.
20. Aune, G. J.; Furuta, T.; Pommier, Y. Ecteinascidin 743: A novel anticancer drug with a unique mechanism of action. Anticancer Drugs 13:545-555; 2002.
21. Damia, G.; Imperatori, L.; Stefanini, M.; D'Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer 66:779-783; 1996.